List view / Grid view

Hit-to-Lead

news

LaVision BioTec reports on the award-winning scientist Peter Friedl and his work imaging cancer growth

25 November 2014 | By LaVison BioTec

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Peter Friedl and his imaging of cancer growth using intravital microscopy...

news

MRC Technology and Yabao Pharmaceuticals announce exclusive partnership in China to develop novel therapeutics for Parkinson’s disease

24 November 2014 | By MRC Technology / Yabao Pharmaceuticals

MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...

news

Professor Paul Workman pledges three-pronged attack on cancer evolution and drug resistance

21 November 2014 | By The Institute of Cancer Research

Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London

A close-up of the EzrA protein, depicted as a ribbon

news

Scientists discover bacteria’s clever defence mechanism

19 November 2014 | By Diamond

Structure of EzrA protein could help identify new antibiotic targets...

news

New Oncology to Collaborate with National Cancer Centre Singapore on Genetic Testing

12 November 2014 | By New Oncology

New Oncology announced that it has entered into a collaboration with the National Cancer Centre Singapore (NCCS)...

news

Daiichi Sankyo selects research partners for TaNeDS collaborative drug discovery project

11 November 2014 | By Daiichi Sankyo Company

Daiichi Sankyo Company, Limited announced that it has selected research partners for its 2014 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project...

news

Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

7 November 2014 | By Felicitex Therapeutics and Selvita

Felicitex Therapeutics and Selvita have announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors...

news

Cancer drug discovery system is broken, global summit hears

24 October 2014 | By The Institute of Cancer Research, London

Leading expert calls for major changes to restock pipeline with innovative cancer treatments...

news

Calixar and Aston University together in collaborative research to tackle multidrug resistance targets

21 October 2014 | By Calixar

Aston University (Birmingham - UK) and Calixar SAS (Lyon-France) have concluded a new research agreement through the “BBSRC Industrial CASE Studentship Competition 2013” framework...

news

Auspherix and Domainex announce collaboration to develop new drugs to treat antibiotic-resistant bacterial infections

15 October 2014 | By Domainex

Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...

Scientists home in on microRNA processing for novel cancer therapies

news

New Oncology and Gustave Roussy announce collaboration on genetic testing

14 October 2014 | By New Oncology

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...

news

Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC

9 October 2014 | By Novartis

Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)...

Research suggests ion channel blocking drugs could be used in cancer therapy

news

Merck Serono to collaborate with The Institute of Cancer Research, London, and Wellcome Trust to co-develop anti-cancer drugs

8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono

Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...

news

OBN celebrates the stars of UK Life Sciences

3 October 2014 | By OBN

OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...

news

Event preview: Drug Discovery Week Europe

3 October 2014 | By GTCbio

From 7-10 October 2014, GTCbio will proudly present its Drug Discovery Week Europe event in the beautiful city of Dublin, Ireland...

Cookie	Type	Duration	Description
cookielawinfo-checkbox-advertising-targeting	persistent	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	persistent	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	session	1 year	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	persistent	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	session	1 year	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Type	Duration	Description
advanced_ads_browser_width	persistent	1 month	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	persistent	2 years	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	persistent	1 month	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	persistent	1 year	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	persistent	2 years	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	persistent	2 years	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	persistent	3 months	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	persistent	1 month	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	persistent	5 months	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Cookie	Type	Duration	Description
bcookie	persistent	2 years	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	persistent	30 minutes	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	session	1 year	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	persistent	1 day	This cookie is set by LinkedIn and used for routing.
lissc	persistent	11 months	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	persistent	2 years	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	persistent	2 years	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	persistent	20 minutes	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	persistent	20 minutes	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	persistent	20 minutes	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	persistent	2 years	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	persistent	1 minute	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	persistent	1 day	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Type	Duration	Description
cf_ob_info	persistent	1 minute	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	persistent	1 minute	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	session	1 year	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	persistent	1 month	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	persistent	Until cleared	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	session	1 year	This cookie is set by Youtube and is used to track the views of embedded videos.

Recommended

Hit-to-Lead